Published in Brain on December 08, 2015
Exosomes in the Pathology of Neurodegenerative Diseases. J Biol Chem (2016) 0.79
Extracellular vesicles in neurodegenerative disease - pathogenesis to biomarkers. Nat Rev Neurol (2016) 0.79
Cell-to-cell transfer of SAA1 protein in a cell culture model of systemic AA amyloidosis. Sci Rep (2017) 0.78
Sexual dimorphism in Parkinson's disease: differences in clinical manifestations, quality of life and psychosocial functioning between males and females. Neuropsychiatr Dis Treat (2017) 0.77
Horizontal Transmission of Cytosolic Sup35 Prions by Extracellular Vesicles. MBio (2016) 0.76
Structure, Distribution, and Genetic Profile of α-Synuclein and Their Potential Clinical Application in Parkinson's Disease. J Mov Disord (2017) 0.75
Plasma exosome concentration may correlate with cognitive impairment in Parkinson's disease. Alzheimers Dement (Amst) (2016) 0.75
The biomarkers of immune dysregulation and inflammation response in Parkinson disease. Transl Neurodegener (2016) 0.75
The release and trans-synaptic transmission of Tau via exosomes. Mol Neurodegener (2017) 0.75
Evaluating Soluble EMMPRIN as a Marker of Disease Activity in Multiple Sclerosis: Studies of Serum and Cerebrospinal Fluid. PLoS One (2016) 0.75
Investigation of Endocytic Pathways for the Internalization of Exosome-Associated Oligomeric Alpha-Synuclein. Front Neurosci (2017) 0.75
The Contribution of α-Synuclein Spreading to Parkinson's Disease Synaptopathy. Neural Plast (2017) 0.75
Exosomes, an Unmasked Culprit in Neurodegenerative Diseases. Front Neurosci (2017) 0.75
Salivary total α-synuclein, oligomeric α-synuclein and SNCA variants in Parkinson's disease patients. Sci Rep (2016) 0.75
Altered Tracer Distribution and Clearance in the Extracellular Space of the Substantia Nigra in a Rodent Model of Parkinson's Disease. Front Neurosci (2017) 0.75
Extracellular Vesicles as a Source of Urological Biomarkers: Lessons Learned From Advances and Challenges in Clinical Applications to Major Diseases. Int Neurourol J (2017) 0.75
Extracellular Mitochondria in Cerebrospinal Fluid and Neurological Recovery After Subarachnoid Hemorrhage. Stroke (2017) 0.75
Perspective Insights of Exosomes in Neurodegenerative Diseases: A Critical Appraisal. Front Aging Neurosci (2017) 0.75
Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging (2002) 22.40
Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology (2005) 21.67
Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology (1996) 8.82
alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc Natl Acad Sci U S A (1998) 8.41
Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med (2008) 6.90
Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci U S A (2009) 6.87
Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science (2012) 6.66
Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron (2011) 4.74
Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice. J Exp Med (2012) 3.98
Intravesicular localization and exocytosis of alpha-synuclein and its aggregates. J Neurosci (2005) 3.93
Cell-produced alpha-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival. J Neurosci (2010) 3.81
Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease. Neurology (2010) 3.70
DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain (2010) 3.57
α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol (2011) 3.12
Exosomes are released by cultured cortical neurones. Mol Cell Neurosci (2006) 3.07
Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J (2006) 2.96
DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology (2007) 2.86
Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm (Vienna) (2003) 2.75
Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma. FASEB J (2003) 2.64
Neurotransmitter-triggered transfer of exosomes mediates oligodendrocyte-neuron communication. PLoS Biol (2013) 2.61
Treatment of brain inflammatory diseases by delivering exosome encapsulated anti-inflammatory drugs from the nasal region to the brain. Mol Ther (2011) 2.61
Characterisation of exosomes derived from human cells by nanoparticle tracking analysis and scanning electron microscopy. Colloids Surf B Biointerfaces (2011) 2.38
Formation of toxic oligomeric alpha-synuclein species in living cells. PLoS One (2008) 2.35
Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission. Neurobiol Dis (2011) 2.32
Higher-order oligomerization targets plasma membrane proteins and HIV gag to exosomes. PLoS Biol (2007) 2.30
Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochem Biophys Res Commun (2006) 2.27
Selective transfer of exosomes from oligodendrocytes to microglia by macropinocytosis. J Cell Sci (2011) 2.25
Prion-like acceleration of a synucleinopathy in a transgenic mouse model. Neurobiol Aging (2011) 2.18
Exosomal cell-to-cell transmission of alpha synuclein oligomers. Mol Neurodegener (2012) 2.11
The prevalence of Parkinson's disease: a systematic review and meta-analysis. Mov Disord (2014) 2.02
Seeded aggregation and toxicity of {alpha}-synuclein and tau: cellular models of neurodegenerative diseases. J Biol Chem (2010) 1.92
Heat-shock protein 70 modulates toxic extracellular α-synuclein oligomers and rescues trans-synaptic toxicity. FASEB J (2010) 1.90
Particle size distribution of exosomes and microvesicles determined by transmission electron microscopy, flow cytometry, nanoparticle tracking analysis, and resistive pulse sensing. J Thromb Haemost (2014) 1.90
Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol (2013) 1.83
Aggregation reroutes molecules from a recycling to a vesicle-mediated secretion pathway during reticulocyte maturation. J Cell Sci (1997) 1.80
CSF Aβ(42) and tau in Parkinson's disease with cognitive impairment. Mov Disord (2010) 1.71
Seeding induced by alpha-synuclein oligomers provides evidence for spreading of alpha-synuclein pathology. J Neurochem (2009) 1.67
Exosomes: vehicles for the transfer of toxic proteins associated with neurodegenerative diseases? Front Physiol (2012) 1.65
Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss? Neurosci Lett (2008) 1.60
Characterization of Lewy body pathology in 12- and 16-year-old intrastriatal mesencephalic grafts surviving in a patient with Parkinson's disease. Mov Disord (2010) 1.47
Extracellular α--synuclein-a novel and crucial factor in Lewy body diseases. Nat Rev Neurol (2014) 1.44
Microglia in the aging brain: relevance to neurodegeneration. Mol Neurodegener (2010) 1.44
Emerging roles of exosomes in neuron-glia communication. Front Physiol (2012) 1.44
Exosomes: vesicular carriers for intercellular communication in neurodegenerative disorders. Cell Tissue Res (2012) 1.31
Quantification of human urinary exosomes by nanoparticle tracking analysis. J Physiol (2013) 1.31
Quantification of α-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies. Biomark Med (2010) 1.27
Nonmotor and diagnostic findings in subjects with de novo Parkinson disease of the DeNoPa cohort. Neurology (2013) 1.26
Blood-brain barrier alterations in ageing and dementia. J Neurol Sci (2009) 1.24
Assessment of α-synuclein secretion in mouse and human brain parenchyma. PLoS One (2011) 1.19
Total CSF α-synuclein is lower in de novo Parkinson patients than in healthy subjects. Neurosci Lett (2012) 1.19
Exosomes for targeted siRNA delivery across biological barriers. Adv Drug Deliv Rev (2012) 1.17
Exosome secretion ameliorates lysosomal storage of cholesterol in Niemann-Pick type C disease. J Biol Chem (2010) 1.12
CSF α-synuclein does not discriminate dementia with Lewy bodies from Alzheimer's disease. J Alzheimers Dis (2010) 1.10
CSF alpha-synuclein levels in dementia with Lewy bodies and Alzheimer's disease. Brain Res (2008) 1.10
Plasma exosomal α-synuclein is likely CNS-derived and increased in Parkinson's disease. Acta Neuropathol (2014) 1.10
Origins of Alzheimer's disease: reconciling cerebrospinal fluid biomarker and neuropathology data regarding the temporal sequence of amyloid-beta and tau involvement. Curr Opin Neurol (2012) 1.04
α-Synuclein in human cerebrospinal fluid is principally derived from neurons of the central nervous system. J Neural Transm (Vienna) (2012) 1.04
Staging of sporadic Parkinson disease-related alpha-synuclein pathology: inter- and intra-rater reliability. J Neuropathol Exp Neurol (2005) 1.03
Tau protein, Abeta42 and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies. Dement Geriatr Cogn Disord (2005) 1.03
Caudo-rostral brain spreading of α-synuclein through vagal connections. EMBO Mol Med (2013) 1.02
Optimizing luciferase protein fragment complementation for bioluminescent imaging of protein-protein interactions in live cells and animals. Methods Enzymol (2004) 1.02
Cell-to-cell transmission of α-synuclein aggregates. Methods Mol Biol (2012) 0.92
Extracellular vesicle sorting of α-Synuclein is regulated by sumoylation. Acta Neuropathol (2015) 0.90
Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson's disease with dementia and dementia with Lewy bodies compared to Alzheimer's disease. Alzheimers Res Ther (2014) 0.89
Development of electrochemiluminescence-based singleplex and multiplex assays for the quantification of α-synuclein and other proteins in cerebrospinal fluid. Methods (2012) 0.88
Cerebrospinal fluid alpha-synuclein as a biomarker for Parkinson's disease diagnosis: a systematic review and meta-analysis. Int J Neurosci (2014) 0.86
Propagation of host disease to grafted neurons: accumulating evidence. Exp Neurol (2009) 0.85
Lewy body pathology in long-term fetal nigral transplants: is Parkinson's disease transmitted from one neural system to another? Neuropsychopharmacology (2009) 0.83
CSF synuclein: adding to the biomarker footprint of dementia with Lewy bodies. J Neurol Neurosurg Psychiatry (2010) 0.77
Serum peptides as candidate biomarkers for dementia with Lewy bodies. Int J Geriatr Psychiatry (2015) 0.76